{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:08:53Z","timestamp":1790644133528,"version":"4.1.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Thessaly Central Library"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Systemic sclerosis is a complex autoimmune disease with widespread fibrosis in skin and internal organs, microvasculopathy, and autoantibodies. The disease causes ischemic changes and leads to impairment of internal organs with reduced quality of life and life expectancy. The pathogenesis is not clearly known but involves adaptive and innate immune cells which infiltrate skin lesions mostly early in the disease process. Current treatment is based on immunosuppressives, but there is a significant unmet therapeutic need, and a new therapeutic approach is required. Autologous haematopoietic stem cell transplantation appears to be an effective therapeutic option for SSc but requires standardization to reduce transplant-related mortality and post-transplant adverse effects. Mesenchymal stem cells (MSCs), exerting immunosuppressive, antifibrotic, and angiogenic actions, appear to be a promising therapeutic option but require further refinement. MSC-derived microvesicles retain MSC functions and circumvent some of the MSC challenges and thus may provide a more favorable therapeutic approach.<\/jats:p>\n                  <jats:p>\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td align=\"left\" colspan=\"2\">\n                              Key Points\u2022\n                              <jats:italic>There are unmet therapeutic needs for systemic sclerosis.<\/jats:italic>\n                              \u2022\n                              <jats:italic>Autologous haematopoietic stem cell transplantation is an effective therapeutic option but needs standarization.<\/jats:italic>\n                              \u2022\n                              <jats:italic>Mesenchymal stem cells are a promising therapeutic option but requires refinement.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s10067-025-07557-y","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T06:48:12Z","timestamp":1751438892000},"page":"3139-3151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Stem cell therapy in systemic sclerosis"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-3314","authenticated-orcid":false,"given":"Lazaros I.","family":"Sakkas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2604-5090","authenticated-orcid":false,"given":"Theodora","family":"Simopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9639-7130","authenticated-orcid":false,"given":"Ioannis","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8343-3810","authenticated-orcid":false,"given":"Christos","family":"Liaskos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8602-0958","authenticated-orcid":false,"given":"Ian C.","family":"Chikanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"7557_CR1","doi-asserted-by":"crossref","unstructured":"Volkman ER, Andreasson K, Smith V (2023) Systemic sclerosis. Lancet 401(10373):304\u2013318. https:\/\/doi.org\/10.1016.S0140-6736(22)01692-0","DOI":"10.1016\/S0140-6736(22)01692-0"},{"issue":"12","key":"7557_CR2","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/ncprheum0346","volume":"2","author":"LI Sakkas","year":"2006","unstructured":"LI Sakkas IC Chikanza CD Platsoucas 2006 Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis Nat Clin Pract Rheumatol 2(12):679 685. https:\/\/doi.org\/10.1038\/ncprheum0346","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"5","key":"7557_CR3","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1093\/rheumatology\/keac578","volume":"62","author":"LI Sakkas","year":"2023","unstructured":"Sakkas LI, Katsiari CG, Daoussis D, Bogdanos DP (2023) The role of B cells in the pathogenesis of systemic sclerosis: an update. Rheumatology (Oxford) 62(5):1780\u20131786. https:\/\/doi.org\/10.1093\/rheumatology\/keac578","journal-title":"Rheumatology (Oxford)"},{"key":"7557_CR4","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1038\/s41467-019-09683-z","volume":"10","author":"R Lande","year":"2019","unstructured":"R Lande EY Lee R Palazzo  2019 CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-\u0391 production in systemic sclerosis Nat Commun 10:1731.https:\/\/doi.org\/10.1038\/s41467-019-09683-z","journal-title":"Nat Commun"},{"issue":"4","key":"7557_CR5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1136\/annrheumdis-2021-221352","volume":"81","author":"B Skaug","year":"2022","unstructured":"Skaug B, Lyons MA, Swindell WR, Salazar GA, Wu M, Tran TM, Charles J, Vershel CP, Mayes MD, Assassi S (2022) Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time. Ann Rheum Dis 81(4):516\u2013523. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221352","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"7557_CR6","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1080\/21645515.2018.1491508","volume":"14","author":"CG Katsiari","year":"2018","unstructured":"CG Katsiari T Simopoulou I Alexiou LI Sakkas 2018 Immunotherapy of systemic sclerosis Hum Vaccin Immunother 14(11):559-2567.https:\/\/doi.org\/10.1080\/21645515.2018.1491508","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"7557_CR7","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/ard-2024-226430","volume":"84","author":"F Del Galdo","year":"2025","unstructured":"Del Galdo F, Lescoat A, Conaghan PG et al (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis 84(1):29\u201340. https:\/\/doi.org\/10.1136\/ard-2024-226430","journal-title":"Ann Rheum Dis"},{"issue":"9790","key":"7557_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"RK Burt SJ Shah K Dill  2011 Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial Lancet 378(9790):98-506.https:\/\/doi.org\/10.1016\/S0140-6736(11)60982-3","journal-title":"Lancet"},{"issue":"24","key":"7557_CR9","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM van Laar","year":"2014","unstructured":"JM Laar van D Farge JK Sont K Naraghi Z Marjanovic J Larghero  2014 Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial JAMA 311(24):490-2498 https:\/\/doi.org\/10.1001\/jama.2014.6368","journal-title":"JAMA"},{"issue":"1","key":"7557_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/nejmoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan KM, Goldmuntz EA, Keyes-Elstein L, McSweeney PA, Pinckney A, Welch B et al (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med 378(1):35\u201347. https:\/\/doi.org\/10.1056\/nejmoa1703327","journal-title":"N Engl J Med"},{"key":"7557_CR11","doi-asserted-by":"publisher","first-page":"941011","DOI":"10.3389\/fimmu.2022.941011","volume":"13","author":"MY Kawashima-Vasconcelos","year":"2022","unstructured":"MY Kawashima-Vasconcelos M Santana-Goncalves DC Zanin-Silva KCR Malmegrim MC Oliveira 2022 Reconstitution of the immune system and clinical correlates after stem cell transplantation for systemic sclerosis Front Immunol 13:941011.https:\/\/doi.org\/10.3389\/fimmu.2022.941011","journal-title":"Front Immunol"},{"issue":"5","key":"7557_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/art.43072","volume":"77","author":"GE Georges","year":"2025","unstructured":"GE Georges D Khanna MH Wene  2025 Autologous nonmyeloablative hematopoietic stem cell transplantation for diffuse cutaneous systemic sclerosis: Identifying disease risk factors for toxicity and long-term outcomes in a prospective, single-arm trial Arthritis Rheumatol 77(5)571-581.https:\/\/doi.org\/10.1002\/art.43072","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"7557_CR13","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1093\/rheumatology\/keq414","volume":"50","author":"H Tsukamoto","year":"2011","unstructured":"H Tsukamoto K Nagafuji T Horiuchi H Mitoma H Niiro Y Arinobu Y Inoue K To T Miyamoto H Iwasaki T Teshima M Harada K Akashi 2011 Analysis of immune reconstitution after autologous CD34+stem\/progenitor cell transplantation for systemic sclerosis: predominant reconstitution of Th1 CD4+ T cells Rheumatology (Oxford) 50(5):44-952.https:\/\/doi.org\/10.1093\/rheumatology\/keq414","journal-title":"Rheumatology (Oxford)"},{"key":"7557_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.723349","volume":"12","author":"PP Strunz","year":"2021","unstructured":"PP Strunz M Froehlich M Gernert EC Schwaneck A Fleischer AC Pecher HP Tony JC Henes M Schmalzing 2021 Immunological adverse effects after autologous hematopoietic stem cell transpplantation in systemic sclerosis patients Front Immunol 12:723349.https:\/\/doi.org\/10.3389\/fimmu.2021.723349","journal-title":"Front Immunol"},{"key":"7557_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1126\/science.284.5411.143","volume":"284","author":"MF Pittenger","year":"1999","unstructured":"MF Pittenger AM Mackay SC Beck  1999 Multilineage potential of adult human mesenchymal stem cells Science 284 143 147","journal-title":"Science"},{"key":"7557_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"M Dominici K Blanc Le I Mueller I Slaper-Cortenbach F Marini D Krause R Deans A Keating D Prockop E Horwitz 2006 Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Cytotherapy 8:15-17.https:\/\/doi.org\/10.1080\/14653240600855905","journal-title":"Cytotherapy"},{"key":"7557_CR17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jcyt.2013.02.006","volume":"15","author":"P Bourin","year":"2013","unstructured":"P Bourin BA Bunnell L Casteilla M Dominici AJ Katz KL March H Redl JP Rubin K Yoshimura JM Gimble 2013 Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal\/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT) Cytotherapy 15:641-648.https:\/\/doi.org\/10.1016\/j.jcyt.2013.02.006","journal-title":"Cytotherapy"},{"key":"7557_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102755","volume":"20","author":"D Farge","year":"2021","unstructured":"D Farge S Loisel P Lansiaux K Tarte 2021 Mesenchymal stromal cells for systemic sclerosis treatment Autoimmun Rev 20:102755.https:\/\/doi.org\/10.1016\/j.autrev.2021.102755","journal-title":"Autoimmun Rev"},{"issue":"1","key":"7557_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1182\/blood-2005-07-2657","volume":"107","author":"A Corcione","year":"2006","unstructured":"A Corcione F Benvenuto E Ferretti D Giunti V Cappiello F Cazzanti M Risso F Gualandi GL Mancardi V Pistoia A Uccelli 2006 Human mesenchymal stem cells modulate B-cell functions Blood 107(1):67-372.https:\/\/doi.org\/10.1182\/blood-2005-07-2657","journal-title":"Blood"},{"issue":"1","key":"7557_CR20","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1634\/stemcells.2004-0359","volume":"24","author":"PA Sotiropoupou","year":"2006","unstructured":"PA Sotiropoupou SA Perez AD Gritzapis CN Baxavanis M Papamichail 2006 Interactions between human mesenchymal stem cells and natural killer cells Stem Cells 24(1):4-85 https:\/\/doi.org\/10.1634\/stemcells.2004-0359","journal-title":"Stem Cells"},{"issue":"9","key":"7557_CR21","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jcyt.2013.02.010","volume":"15","author":"M Kampera","year":"2013","unstructured":"M Kampera J Galipeau Y Shi  2013 Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal Cytotherapy 15(9):1054-61 https:\/\/doi.org\/10.1016\/j.jcyt.2013.02.010","journal-title":"Cytotherapy"},{"issue":"3","key":"7557_CR22","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/cei.12423","volume":"178","author":"M Li","year":"2014","unstructured":"M Li X Sun X Kuang Y Liao H Li D Luo (2014) Mesenchymal stem cells suppress CD8+ T cell-mediated activation by suppressing natural killer group 2, member D protein receptor expression and secretion of prostaglandin E2, indoleamine 2, 3-dioxygenase and transforming growth factor-\u03b2 Clin Exp Immunol 178(3):16-524.https:\/\/doi.org\/10.1111\/cei.12423","journal-title":"Clin Exp Immunol"},{"key":"7557_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13287-015-0222-y","volume":"6","author":"F Benvenuto","year":"2015","unstructured":"F Benvenuto A Voci E Carminati F Gualandi G Mancardi A Uccelli L Vergani 2015 Human mesenchymal stem cells target adhesion molecules and receptors involved in T cell extravasation Stem Cell Res Ther 6:245.https:\/\/doi.org\/10.1186\/s13287-015-0222-y","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"7557_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/scrt34","volume":"1","author":"BA Bunnell","year":"2010","unstructured":"BA Bunnell AM Betancourt DE Sullivan 2010 New concepts on the immune modulation mediated by mesenchymal stem cells Stem Cell Res Ther 1(5):34.https:\/\/doi.org\/10.1186\/scrt34","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"7557_CR25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/bmb\/ldt031","volume":"108","author":"SM Watt","year":"2013","unstructured":"SM Watt F Gullo M Garde van der D Markeson R Camicia CP Khoo JJ Zwaginga 2013 The angiogenic properties of mesenchymal stem\/stromal cells and their therapeutic potential Br Med Bull 108(1):5-53.https:\/\/doi.org\/10.1093\/bmb\/ldt031","journal-title":"Br Med Bull"},{"issue":"1","key":"7557_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13075-022-02915-6","volume":"24","author":"T Suzuka","year":"2022","unstructured":"Suzuka T, Kotani T, Saito T, Matsuda S, Sato T, Takeuchi T (2022) Therapeutic effects of adipose-derived mesenchymal stem\/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis. Arthritis Res Ther 24(1):228. https:\/\/doi.org\/10.1186\/s13075-022-02915-6","journal-title":"Arthritis Res Ther"},{"key":"7557_CR27","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/jcp.21068","volume":"212","author":"GE Kilroy","year":"2007","unstructured":"GE Kilroy SJ Foster X Wu J Ruiz S Sherwood A Heifetz JW Ludlow DM Stricker S Potiny P Green  2007 Cytokine profile of human adipose-derived stem cells: Expression of angiogenic, hematopoietic, and pro-inflammatory factors J Cell Physiol 212:702-709.https:\/\/doi.org\/10.1002\/jcp.21068","journal-title":"J Cell Physiol"},{"issue":"4","key":"7557_CR28","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1189\/jlb.0307140","volume":"82","author":"I Rasmusson","year":"2007","unstructured":"I Rasmusson M Uhlin K Blanc Le V Levitsky 2007 Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes J Leukoc Biol 82(4):87-893.https:\/\/doi.org\/10.1189\/jlb.0307140","journal-title":"J Leukoc Biol"},{"issue":"9","key":"7557_CR29","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1111\/j.1582-4934.2011.01509.x","volume":"16","author":"S Schu","year":"2012","unstructured":"Schu S, Nosov M, O\u2019Flynn L, Shaw G, Treacy O, Barry M, Murhy M, O\u2019brien T, Ritter T (2012) Immunogenicity of allogeneic mesenchymal stem cells. J Cell Mol Med 16(9):2094\u20132103. https:\/\/doi.org\/10.1111\/j.1582-4934.2011.01509.x","journal-title":"J Cell Mol Med"},{"issue":"6","key":"7557_CR30","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1182\/blood-2005-11-011650","volume":"108","author":"AJ Nauta","year":"2006","unstructured":"AJ Nauta G Westerhuis AB Kruisselbrink EGA Lurvink R Willemze WE Fibbe 2006 Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting Blood 108(6):114-2120.https:\/\/doi.org\/10.1182\/blood-2005-11-011650","journal-title":"Blood"},{"issue":"4","key":"7557_CR31","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1136\/ard.2007.071233","volume":"67","author":"J Larghero","year":"2008","unstructured":"J Larghero D Farge A Braccini S Lecourt A Scherberich E Fo\u00efs F Verrecchia T Daikeler E Gluckman A Tyndall C Bocelli-Tyndall 2008 Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis Ann Rheum Dis 67(4):43-449.https:\/\/doi.org\/10.1136\/ard.2007.071233","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"7557_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/cei.12111","volume":"173","author":"P Cipriani","year":"2013","unstructured":"P Cipriani P Benedetto Di V Liakouli B Papa Del M Padova Di M Ianni Di A Marrelli E Alesse R Giacomelli 2013 Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy Clin Exp Immunol 173(2):95-206.https:\/\/doi.org\/10.1111\/cei.12111","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"7557_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153101","volume":"11","author":"B Hegner","year":"2016","unstructured":"B Hegner T Schaub R Catar  2016 Intrinsic deregulation of vascular smooth muscle and myofibroblast differentiation in mesenchymal stromal cells from patients with systemic sclerosis PLoS ONE 11(4):0153101.https:\/\/doi.org\/10.1371\/journal.pone.0153101","journal-title":"PLoS ONE"},{"issue":"6","key":"7557_CR34","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/art.22698","volume":"56","author":"P Cipriani","year":"2007","unstructured":"P Cipriani S Guiducci I Miniati (2007) Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis.Arthritis Rheum 56(6):1994-204.https:\/\/doi.org\/10.1002\/art.22698","journal-title":"Arthritis Rheum"},{"key":"7557_CR35","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1136\/ard.2011.150607","volume":"70","author":"S Guiducci","year":"2011","unstructured":"S Guiducci M Manetti E Romano  2011 Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro Ann Rheum Dis 70:2011-2021.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7557_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13287-016-0444-7","volume":"8","author":"M Griffin","year":"2017","unstructured":"M Griffin CM Ryan O Pathan D Abraham CP Denton PEM Butler 2017 Characteristics of human adipose derived stem cells in scleroderma in comparison to sex and age matched normal controls: implications for regenerative medicine Stem Cells Res Ther 8(1):23. https:\/\/doi.org\/10.1186\/s13287-016-0444-7","journal-title":"Stem Cells Res Ther"},{"issue":"5","key":"7557_CR37","doi-asserted-by":"publisher","first-page":"841","DOI":"10.3727\/096368917X694822","volume":"26","author":"C Capelli","year":"2017","unstructured":"C Capelli E Zaccara P Cipriani P Benedetto Di W Maglione R Andracco  2017 Phenotypical and functional characteristics of in vitro-expanded adipose-derived mesenchymal stromal cells from patients with systematic sclerosis Cell Transplant 26(5):841-854. https:\/\/doi.org\/10.3727\/096368917X694822","journal-title":"Cell Transplant"},{"key":"7557_CR38","doi-asserted-by":"publisher","first-page":"096368972094568","DOI":"10.1177\/0963689720945682","volume":"29","author":"E Kuca-Warnawin","year":"2020","unstructured":"E Kuca-Warnawin I Janicka P Szczesny  2020 Modulation of T-cell activation markers expression by the adipose tissue\u2013derived mesenchymal stem cells of patients with rheumatic diseases Cell Transplant 29:0963689720945682. https:\/\/doi.org\/10.1177\/0963689720945682","journal-title":"Cell Transplant"},{"issue":"8","key":"7557_CR39","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/art.41267","volume":"72","author":"Z Taki","year":"2020","unstructured":"Z Taki E Gostjeva W Thilly  2020 Pathogenic activation of mesenchymal stem cells is induced by the disease microenvironment in systemic sclerosis Arthritis Rheumatol 72(8):1361-1374. https:\/\/doi.org\/10.1002\/art.41267","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"7557_CR40","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.1038\/s41598-019-43638-0","volume":"9","author":"P Di Benedetto","year":"2019","unstructured":"P Benedetto Di N Panzera P Cipriani V Mastroiaco A Tessitore V Liakouli P Ruscitti O Berardicurti F Carubbi G Guggino A Bianchi A Marco Di F Ciccia E Alesse R Giacomelli 2019 Mesenchymal stem cells of systemic sclerosis patients, deerived from different sources, show a profibrotic microRNA profiling Sci Rep 9(1):7144. https:\/\/doi.org\/10.1038\/s41598-019-43638-0","journal-title":"Sci Rep"},{"issue":"3","key":"7557_CR41","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/annrheumdis-2018-214218","volume":"78","author":"J Magalon","year":"2019","unstructured":"J Magalon M Velier S Simoncini P Fran\u00e7ois B Bertrand A Daumas A Benyamine R Boissier L Arnaud L Lyonnet S Fernandez F Dignat-George D Casanova B Guillet B Granel P Paul F Sabatier 2019 Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis Ann Rheum Dis 78(3):391-398. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214218","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7557_CR42","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s12016-021-08892-z","volume":"64","author":"X Zhuang","year":"2023","unstructured":"X Zhuang X Hu S Zhang X Li X Yuan Y Wu 2023 Mesenchymal stem cell-based therapy as a new approach for the treatment of systemic sclerosis Clin Rev Allergy Immunol 64(3):284-320. https:\/\/doi.org\/10.1007\/s12016-021-08892-z","journal-title":"Clin Rev Allergy Immunol"},{"issue":"9047","key":"7557_CR43","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/s0140-6736(05)64864-7","volume":"349","author":"A Tyndall","year":"1997","unstructured":"A Tyndall C Black J Finke J Winkler R Mertlesmann HH Peter A Gratwohl 1997 Treatment of systemic sclerosis with autologous haemopoietic stem cell transplantation Lancet 349(9047):254. https:\/\/doi.org\/10.1016\/s0140-6736(05)64864-7","journal-title":"Lancet"},{"issue":"6","key":"7557_CR44","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/ard.60.6.577","volume":"60","author":"M Binks","year":"2001","unstructured":"M Binks JR Passweg D Furst P McSweeney K Sullivan C Besenthal  2001 Phase I\/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease Ann Rheum Dis 60(6):577-584.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7557_CR45","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1046\/j.1365-2141.2002.03895.x","volume":"119","author":"D Farge","year":"2002","unstructured":"D Farge JP Marolleau S Zohar  2002 Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study Br J Haematol 119(3):726-739. https:\/\/doi.org\/10.1046\/j.1365-2141.2002.03895.x","journal-title":"Br J Haematol"},{"issue":"5","key":"7557_CR46","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1182\/blood.V100.5.1602.h81702001602_1602_1610","volume":"100","author":"PA McSweeney","year":"2002","unstructured":"PA McSweeney RA Nash KM Sullivan J Storek LJ Crofford R Dansey  2002 High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes Blood 100(5):1602-1610.","journal-title":"Blood"},{"issue":"4","key":"7557_CR47","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/ard.2005.037879","volume":"65","author":"H Tsukamoto","year":"2006","unstructured":"H Tsukamoto K Nagafuji T Horiuchi T Miyamoto K Aoki K Takase  2006 A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease Ann Rheum Dis 65(4):508-514. https:\/\/doi.org\/10.1136\/ard.2005.037879","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"7557_CR48","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1182\/blood-2007-02-072389","volume":"110","author":"RA Nash","year":"2007","unstructured":"RA Nash PA McSweeney LJ Crofford  2007 High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study Blood 110(4):1388-1396. https:\/\/doi.org\/10.1182\/blood-2007-02-072389","journal-title":"Blood"},{"issue":"6","key":"7557_CR49","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/sj.bmt.1705782","volume":"40","author":"Y Oyama","year":"2007","unstructured":"Y Oyama WG Barr L Statkute T Corbridge EA Gonda B Jovanovic A Testori RK Burt 2007 Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis Bone Marrow Transplant 40(6):549-555. https:\/\/doi.org\/10.1038\/sj.bmt.1705782","journal-title":"Bone Marrow Transplant"},{"issue":"9872","key":"7557_CR50","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/S0140-6736(12)62114-X","volume":"381","author":"RK Burt","year":"2013","unstructured":"RK Burt MC Oliveira SJ Shah DA Moraes B Simoes M Gheorghiade  2013 Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis Lancet 381(9872):1116-1124. https:\/\/doi.org\/10.1016\/S0140-6736(12)62114-X","journal-title":"Lancet"},{"issue":"2","key":"7557_CR51","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1093\/mr\/roac026","volume":"33","author":"K Higashitani","year":"2023","unstructured":"K Higashitani K Takase-Minegishi R Yoshimi Y Kirino N Hamada H Nagai  2023 Benefits and risks of haematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis Mod Rheumatol 33(2):330-337. https:\/\/doi.org\/10.1093\/mr\/roac026","journal-title":"Mod Rheumatol"},{"issue":"1","key":"7557_CR52","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13075-022-02948-x","volume":"24","author":"N Blank","year":"2022","unstructured":"N Blank M Schmalzing P Moinzadeh  2022 Autologous hematopoietic stem cell transplantation improves long-term survival-data from a national registry Arthritis Res Ther 24(1):258. https:\/\/doi.org\/10.1186\/s13075-022-02948-x","journal-title":"Arthritis Res Ther"},{"key":"7557_CR53","doi-asserted-by":"publisher","unstructured":"Keret S, Kaly L, Schett G, Bergmann C, Feldman E, Zuckerman T, et al (2025) Neutrophil-to-lymphocyte ratio as a biomarker for clinical response after autologous hematopoietic stem cell transplantation in systemic sclerosis. Rheumatology(Oxford) 64(5):3160\u20133165. https:\/\/doi.org\/10.1093\/rheumatology\/keae606","DOI":"10.1093\/rheumatology\/keae606"},{"key":"7557_CR54","doi-asserted-by":"publisher","unstructured":"Pugnet G, Petermann A, Collot S, et al (2023) Changes on chest HRCT in systemic sclerosis-related interstitial lung disease after autologous haematopoietic stem cell transplantation. Rheumatology (Oxford) 62(SI):SI32-SI42. https:\/\/doi.org\/10.1093\/rheumatology\/keac319","DOI":"10.1093\/rheumatology\/keac319"},{"issue":"2","key":"7557_CR55","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/acr.24785","volume":"75","author":"L Keyes-Elstein","year":"2023","unstructured":"L Keyes-Elstein A Pinckney E Goldmuntz  2023 Clinical and molecular findings after autologous stem cell transplantation or cyclophosphamide for scleroderma: handling missing longitudinal data Arthritis Care Res (Hoboken) 75(2):307-316. https:\/\/doi.org\/10.1002\/acr.24785","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"7557_CR56","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1007\/s10067-023-06766-7","volume":"42","author":"MMK Woo","year":"2023","unstructured":"MMK Woo D Levin DY Li 2023 Esophageal motility in systemic sclerosis before and after autologous hematopoietic cell transplantation Clin Rheumatol 42(12):3267-3274. https:\/\/doi.org\/10.1007\/s10067-023-06766-7","journal-title":"Clin Rheumatol"},{"issue":"1","key":"7557_CR57","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s42358-021-00166-8","volume":"61","author":"\u00c1 Henrique-Neto","year":"2021","unstructured":"\u00c1 Henrique-Neto MYK Vasconcelos JBE Dias DA Moraes de MS Gon\u00e7alves DC Zanin-Silva  2021 Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience Adv Rheumatol 61(1):9. https:\/\/doi.org\/10.1186\/s42358-021-00166-8","journal-title":"Adv Rheumatol"},{"key":"7557_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.817893","volume":"12","author":"EC Gerneck","year":"2022","unstructured":"EC Gerneck HP Tony M Frohlich EC Schwaneck M Schmalzing 2022 Immunosuppressive therapy after autologous hematopoietic stem cell transplantation in systemic sclerosis patients-high efficacy of rituximab Front Immunol 12:817893https:\/\/doi.org\/10.3389\/fimmu.2021.817893","journal-title":"Front Immunol"},{"issue":"3","key":"7557_CR59","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1136\/ard-2021-221925","volume":"82","author":"JZ Adamska","year":"2023","unstructured":"JZ Adamska A Zia MS Bloom LJ Crofford DE Furst  2023 Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more na\u00efve state in patients with systemic sclerosis Ann Rheum Dis 82(3):357-364. https:\/\/doi.org\/10.1136\/ard-2021-221925","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7557_CR60","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1084\/jem.20041679","volume":"201","author":"PA Muraro","year":"2005","unstructured":"PA Muraro DC Douek A Packer K Chung FJ Guenaga R Cassiani-Ingoni  2005 Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients J Exp Med 201(5):805-816. https:\/\/doi.org\/10.1084\/jem.20041679","journal-title":"J Exp Med"},{"issue":"1","key":"7557_CR61","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1182\/blood-2008-07-168286","volume":"113","author":"T Alexander","year":"2009","unstructured":"T Alexander A Thiel O Rosen  2009 Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system Blood 113(1):214-223. https:\/\/doi.org\/10.1182\/blood-2008-07-168286","journal-title":"Blood"},{"issue":"12","key":"7557_CR62","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1093\/rheumatology\/keab257","volume":"60","author":"JR Lima-Junior","year":"2021","unstructured":"JR Lima-Junior LCM Arruda MS Goncalves  2021 Autologous haematopoietic stem cell transplantation restores the suppressive capacity of regulatory B cells in systemic sclerosis patients Rheumatology (Oxford) 60(12):5538-5548. https:\/\/doi.org\/10.1093\/rheumatology\/keab257","journal-title":"Rheumatology (Oxford)"},{"key":"7557_CR63","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1136\/annrheumdis-2019-215770","volume":"78","author":"S Assassi","year":"2019","unstructured":"S Assassi X Wang G Chen E Goldmuntz L Keyes-Elstein J Ying PK Wallace J Turner WJ Zheng V Pascual  2019 Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures Ann Rheum Dis 78:1371-1378. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215770","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7557_CR64","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.bbmt.2018.01.020","volume":"24","author":"R Shouval","year":"2018","unstructured":"R Shouval N Furie A Nagler A Gafter-Gvili 2018 Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis Biol Blood Marrow Transplant 24(5):937-944. https:\/\/doi.org\/10.1016\/j.bbmt.2018.01.020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"7557_CR65","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00432-024-05815-1","volume":"150","author":"V Ryka","year":"2024","unstructured":"V Ryka DB Vangala T Mika  2024 High-dose chemotherapy and autologous hematopoietic stem cell transplantation for progressive systemic sclerosis: a retrospective study of outcome and prognostic factors J Cancer Res Clin Oncol 150(6):301. https:\/\/doi.org\/10.1007\/s00432-024-05815-1","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"7557_CR66","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/bmt.2017.56","volume":"52","author":"D Farge","year":"2017","unstructured":"D Farge RK Burt MC Oliveira E Mousseaux M Rovira Z Marjanovic  2017 Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European society for blood and marrow transplantation autoimmune diseases working party and collaborating partners Bone Marrow Transplant 52(11):1495-1503. https:\/\/doi.org\/10.1038\/bmt.2017.56","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"7557_CR67","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/23971983221145639","volume":"8","author":"R Penglase","year":"2023","unstructured":"R Penglase L Girgis H Englert X Brennan A Jabbour E Kotlyar D Ma J Moore 2023 Cardiotoxicity in autologous haematopoietic stem cell transplantation for systemic sclerosis J Scleroderma Relat Disord 8(2):87-100. https:\/\/doi.org\/10.1177\/23971983221145639","journal-title":"J Scleroderma Relat Disord"},{"issue":"12","key":"7557_CR68","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1093\/rheumatology\/keae268","volume":"63","author":"S Keret","year":"2024","unstructured":"Keret S, Chutko B, Bobrecky-Mery I, Wolak A, Hardak E et al (2024) Cardiac safe hematopoietic stem cell transplantation protocol for systemic sclerosis with myocarditis- a two-step approach. Rheumatology (Oxford) 63(12):e328\u2013e330. https:\/\/doi.org\/10.1093\/rheumatology\/keae268","journal-title":"Rheumatology (Oxford)"},{"key":"7557_CR69","doi-asserted-by":"publisher","unstructured":"Sharif MO, Leavis HL, van Paassen A, Timmermans SAMEG, Ton E, van Laar JM, Spierings L (2021) Severe thrombotic microangiopathy after autologous stem cell transplantation in systemic sclerosis: a case report. Rheumatol(Oxford) 60(9):e326-e328. https:\/\/doi.org\/10.1093\/rheumatology\/keab239","DOI":"10.1093\/rheumatology\/keab239"},{"key":"7557_CR70","doi-asserted-by":"publisher","unstructured":"Bruerta S, Sidanmat H, Molony DA, Mayes MD, Suarez-Almazor ME, Krause K, Lopez-Olivo MA (2022) Stem cell transplantation for systemic sclerosis. Cochrane Database Syst Rev 7(7):CD011819. https:\/\/doi.org\/10.1002\/14651858.CD011819.pub2","DOI":"10.1002\/14651858.CD011819.pub2"},{"key":"7557_CR71","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/bmt.2015.299","volume":"51","author":"MC Oliveira","year":"2016","unstructured":"MC Oliveira M Labopin J Henes J Moore N Papa Del A Cras I Sakellari R Schroers HU Scherer A Cuneo  2016 Does ex vivo CD34+ positive selection influence outcome after autologous hematopoietic stem cell transplantation in systemic sclerosis patients? Bone Marrow Transplant 51:501-505. https:\/\/doi.org\/10.1038\/bmt.2015.299","journal-title":"Bone Marrow Transplant"},{"key":"7557_CR72","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13075-019-1823-0","volume":"21","author":"M Ayano","year":"2019","unstructured":"M Ayano H Tsukamoto H Mitoma Y Kimoto M Akahoshi Y Arinobu  2019 CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation in the treatment of severe systemic sclerosis: a post hoc analysis of a phase I\/II clinical trial conducted in Japan Arthritis Res Ther 21:30. https:\/\/doi.org\/10.1186\/s13075-019-1823-0","journal-title":"Arthritis Res Ther"},{"key":"7557_CR73","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3324\/haematol.2019.230128","volume":"106","author":"J Henes","year":"2021","unstructured":"J Henes MC Oliveira M Labopin M Badoglio HU Scherer N Papa Del T Daikeler M Schmalzing R Schroers T Martin  2021 Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European society for blood and marrow transplantation autoimmune disease working party Haematologica 106:375-383. https:\/\/doi.org\/10.3324\/haematol.2019.230128","journal-title":"Haematologica"},{"key":"7557_CR74","doi-asserted-by":"publisher","unstructured":"Pecher AC, Ach KR, Vogel W, Henes JH (2023) Mobilization with reduced cyclophosphamide for autologous stem cell transplantation is feasible in patients with systemic sclerosis. Rheumatology (Oxford) 62(SI):SI107-SI113. https:\/\/doi.org\/10.1093\/rheumatology\/keac455","DOI":"10.1093\/rheumatology\/keac455"},{"issue":"6","key":"7557_CR75","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1002\/art.21908","volume":"54","author":"RA Nash","year":"2006","unstructured":"RA Nash PA McSweeney JL Nelson M Wener GE Georges AA Langston  2006 Allogeneic marrow transplantation in patients with severe systemic sclerosis: resolution of dermal fibrosis Arthritis Rheum 54(6):1982-1986. https:\/\/doi.org\/10.1002\/art.21908","journal-title":"Arthritis Rheum"},{"issue":"1","key":"7557_CR76","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/bmt.2008.424","volume":"44","author":"T Daikeler","year":"2009","unstructured":"Daikeler T, Hugle T, Farge D et al (2009) Allogeneic hematopoietic SCT for patients with autoimmune diseases. Bone Marrow Transplant 44(1):27\u201333. https:\/\/doi.org\/10.1038\/bmt.2008.424","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"7557_CR77","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1136\/ard.2010.144360","volume":"70","author":"J Fransen","year":"2011","unstructured":"J Fransen D Popa-Diaconu R Hesselstrand P Carreira  2011 Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres Ann Rheum Dis 70(10):1788-1792. https:\/\/doi.org\/10.1136\/ard.2010.144360","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7557_CR78","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/rheumatology\/keab604","volume":"61","author":"J Spierings","year":"2022","unstructured":"J Spierings SI Nihtyanova E Derrett-Smith KEN Clark JM Laar van V Ong CP Denton 2022 Outcomes linked to eligibility for stem cell transplantation trials in diffuse cutaneous systemic sclerosis Rheumatology (Oxford) 61(5):1948-1956. https:\/\/doi.org\/10.1093\/rheumatology\/keab604","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"7557_CR79","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-044483","volume":"11","author":"J Spierings","year":"2021","unstructured":"J Spierings A Rhenen van PMW Welsing  2021 A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol BMJ Open 11(3):e044483.https:\/\/doi.org\/10.1136\/bmjopen-2020-044483","journal-title":"BMJ Open"},{"issue":"1","key":"7557_CR80","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13075-024-03408-4","volume":"26","author":"N Del Papa","year":"2024","unstructured":"N Papa Del S Cavalli A Rindone  2024 Long-term outcome of autologous haematopoietic stem cell transplantation in patients with systemic sclerosis: a comparison with patients treated with rituximab and with traditional immunosuppressive agents Arthritis Res Ther 26(1):182. https:\/\/doi.org\/10.1186\/s13075-024-03408-4","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"7557_CR81","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1002\/art.42850","volume":"76","author":"K Gregory","year":"2024","unstructured":"Gregory K, Hansen D, Penglase R, Apostolopoulos D et al (2024) Outcomes of patients with diffuse systemic sclerosis eligible for autologous stem cell transplantation treated with conventional therapy. Arthritis Rheumatol 76(8):1294\u20131302. https:\/\/doi.org\/10.1002\/art.42850","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"7557_CR82","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1093\/rheumatology\/kead457","volume":"63","author":"S Keret","year":"2024","unstructured":"S Keret I Henig T Zuckerman L Kaly  2024 Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy Rheumatology (Oxford) 63(6):1534-1538. https:\/\/doi.org\/10.1093\/rheumatology\/kead457","journal-title":"Rheumatology (Oxford)"},{"key":"7557_CR83","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/j.transproceed.2008.01.080","volume":"40","author":"F Zhao","year":"2008","unstructured":"F Zhao YF Zhang YG Liu JJ Zhou ZK Li CG Wu HW Qi 2008 Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats Transplant Proc 40:1700-1705. https:\/\/doi.org\/10.1016\/j.transproceed.2008.01.080","journal-title":"Transplant Proc"},{"key":"7557_CR84","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2353\/ajpath.2009.080629","volume":"175","author":"Y Moodley","year":"2009","unstructured":"Y Moodley D Atienza U Manuelpillai CS Samuel J Tchongue S Ilancheran R Boyd A Trounson 2009 Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury Am J Pathol 175:303-313 https:\/\/doi.org\/10.2353\/ajpath.2009.080629","journal-title":"Am J Pathol"},{"key":"7557_CR85","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3892\/etm.2020.9387","volume":"20","author":"Y Yang","year":"2020","unstructured":"Y Yang S Zhu Y Li Q Lu Q Zhang L Su Y Zhao Y Luo Y Liu 2020 Human umbilical cord mesenchymal stem cells ameliorate skin fibrosis development in a mouse model of bleomycin-induced systemic sclerosis Exp Ther Med 20:257. https:\/\/doi.org\/10.3892\/etm.2020.9387","journal-title":"Exp Ther Med"},{"key":"7557_CR86","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/art.39477","volume":"68","author":"AT Maria","year":"2016","unstructured":"AT Maria K Toupet C Bony N Pirot MC Vozenin B Petit P Roger F Batteux A Quellec Le C Jorgensen  2016 Antifibrotic, antioxidant, and immunomodulatory effects of mesenchymal stem cells in HOCl-induced systemic sclerosis Arthritis Rheumatol 68:1013-1025. https:\/\/doi.org\/10.1002\/art.39477","journal-title":"Arthritis Rheumatol"},{"key":"7557_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2021.101671","volume":"73","author":"DF Elessawi","year":"2021","unstructured":"DF Elessawi H Gabr MMM Badawy TA Gheita 2021 Therapeutic potential of mesenchymal stem cells for scleroderma induced in mouse model Tissue Cell 73:101671.https:\/\/doi.org\/10.1016\/j.tice.2021.101671","journal-title":"Tissue Cell"},{"key":"7557_CR88","doi-asserted-by":"publisher","first-page":"262","DOI":"10.15283\/ijsc20002","volume":"14","author":"X Jin","year":"2021","unstructured":"X Jin J Hou K Zheng D Wei A Zhang S Wang H Mei C Li L Cheng X Sun 2021 Umbilical cord mesenchymal stem cells for inhibiting the fibrosis and autoimmune development in HOCl-induced systemic scleroderma mouse model Int J Stem Cells 14:262-274. https:\/\/doi.org\/10.15283\/ijsc20002","journal-title":"Int J Stem Cells"},{"key":"7557_CR89","doi-asserted-by":"publisher","first-page":"e0157624","DOI":"10.1128\/spectrum.01576-24","volume":"24","author":"L Zhang","year":"2025","unstructured":"Zhang L, Wang H, Zhao L, Zhang J, Sun W, Chu J et al (2025) Unraveling the interplay between mesenchymal stem cells, gut microbiota, and systemic sclerosis: therapeutic implications. Microbiol Spectr 24:e0157624. https:\/\/doi.org\/10.1128\/spectrum.01576-24","journal-title":"Microbiol Spectr"},{"issue":"2","key":"7557_CR90","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/1756-185X.13764","volume":"23","author":"O Ai","year":"2020","unstructured":"O Ai T Matsishita A Komuro  2020 Adipose-derived stromal\/stem cells successfully attenuate the fibrosis of scleroderma mouse models Int J Rheum Dis 23(2):216-225. https:\/\/doi.org\/10.1111\/1756-185X.13764","journal-title":"Int J Rheum Dis"},{"key":"7557_CR91","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jaut.2016.03.013","volume":"70","author":"ATJ Maria","year":"2016","unstructured":"ATJ Maria K Toupet M Maumus  2016 Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis J Autoimmun 70:31-39. https:\/\/doi.org\/10.1016\/j.jaut.2016.03.013","journal-title":"J Autoimmun"},{"issue":"3056","key":"7557_CR92","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.3389\/fimmu.2018.03056.eCollection","volume":"9","author":"ATJ Maria","year":"2018","unstructured":"ATJ Maria P Rozier G Fonteneau  2018 iNOS activity is required for the therapeutic effect of mesenchymal stem cells in experimental systemic sclerosis Front Immunol 9(3056):2018. https:\/\/doi.org\/10.3389\/fimmu.2018.03056.eCollection","journal-title":"Front Immunol"},{"issue":"9","key":"7557_CR93","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.jid.2017.02.986","volume":"137","author":"JY Lim","year":"2017","unstructured":"Lim JY, Ryu DB, Lee SE, Park G, Min CK (2017) Mesenchymal stem cells (MSCs) attenuate cutaneous sclerodermatous graft-versus-host disease (Scl-GVHD) through inhibition of immune cell infiltration in a mouse model. J Invest Dermatol 137(9):1895\u20131904. https:\/\/doi.org\/10.1016\/j.jid.2017.02.986","journal-title":"J Invest Dermatol"},{"issue":"2","key":"7557_CR94","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00441-022-03716-8","volume":"391","author":"N Ganesan","year":"2023","unstructured":"N Ganesan YD Chang SC Hung JL Lan JW Liao ST Fu CC Lee 2023 Mesenchymal stem cells suppressed skin and lung inflammation and fibrosis in topoisomerase I-induced systemic sclerosis associated with lung disease mouse model Cell Tissue Res 391(2):323-337. https:\/\/doi.org\/10.1007\/s00441-022-03716-8","journal-title":"Cell Tissue Res"},{"issue":"5","key":"7557_CR95","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3727\/096368912X639017","volume":"22","author":"N Scuderi","year":"2013","unstructured":"N Scuderi S Ceccarelli MG Onesti  2013 Human adipose-derived stromal cells for cell-based therapies in the treatment of systemic sclerosis Cell Transplant 22(5):779-795. https:\/\/doi.org\/10.3727\/096368912X639017","journal-title":"Cell Transplant"},{"key":"7557_CR96","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.3727\/096368914X685636","volume":"24","author":"N Del Papa","year":"2015","unstructured":"N Papa Del G Luca Di D Sambataro E Zaccara W Maglione A Gabrielli P Fraticelli G Moroncini L Beretta A Santaniello  2015 Regional implantation of autologous adipose tissue-derived cells induces a prompt healing of long-lasting indolent digital ulcers in patients with systemic sclerosis Cell Transplant 24:2297-2305. https:\/\/doi.org\/10.3727\/096368914X685636","journal-title":"Cell Transplant"},{"key":"7557_CR97","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13075-018-1792-8","volume":"21","author":"N Del Papa","year":"2019","unstructured":"N Papa Del G Luca Di R Andracco E Zaccara W Maglione F Pignataro A Minniti C Vitali 2019 Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study Arthritis Res Ther 21:7. https:\/\/doi.org\/10.1186\/s13075-018-1792-8","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"7557_CR98","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/rheumatology\/ket432","volume":"53","author":"G Takagi","year":"2014","unstructured":"G Takagi M Miyamoto S Tara S Kirinoki-Ichikawa Y Kubota T Hada I Takagi K Mizuno 2014 Therapeutic vascular angiogenesis for intractable macroangiopathy-related digital ulcer in patients with systemic sclerosis: a pilot study Rheumatology (Oxford) 53(5):854-859. https:\/\/doi.org\/10.1093\/rheumatology\/ket432","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"7557_CR99","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10165-010-0274-x","volume":"20","author":"Y Ishigatsubo","year":"2010","unstructured":"Y Ishigatsubo A Ihata H Kobayashi M Hama Y Kirino A Ueba  2010 Therapeutic angiogenesis in patients with systemic sclerosis by autologous transplantation of bone-marrow-derived cells Mod Rheumatol 20(3):263-272. https:\/\/doi.org\/10.1007\/s10165-010-0274-x","journal-title":"Mod Rheumatol"},{"issue":"3","key":"7557_CR100","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1253\/circj.CJ-18-1044","volume":"83","author":"K Shoji","year":"2019","unstructured":"K Shoji K Yanishi R Yoshimi N Hamada K Kondo K Fujimoto  2019 Impact of therapeutic angiogenesis using autologous bone marrow-derived mononuclear cells implantation in critical limb ischemia with scleroderma-subanalysis of the long-term clinical outcomes survey Circ J 83(3):662-671. https:\/\/doi.org\/10.1253\/circj.CJ-18-1044","journal-title":"Circ J"},{"issue":"12","key":"7557_CR101","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1136\/annrheumdis-2014-205681","volume":"74","author":"B Granel","year":"2015","unstructured":"B Granel A Daumas E Jouve  2015 Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial Ann Rheum Dis 74(12):2175-2182. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205681","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7557_CR102","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.retram.2016.10.006","volume":"65","author":"A Daumas","year":"2017","unstructured":"A Daumas J Magalon E Jouve R Truillet D Casanova L Giraudo J Veran A Benyamine F Dignat-George G Magalon F Sabatier B Granel 2017 Long-term follow-up after autologous adipose-derived stromal vascular fraction injection into fingers in systemic sclerosis patients Curr Res Trans Med 65(1):40-43. https:\/\/doi.org\/10.1016\/j.retram.2016.10.006","journal-title":"Curr Res Trans Med"},{"key":"7557_CR103","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.3390\/jcm9093023","volume":"9","author":"Y Park","year":"2020","unstructured":"Y Park YJ Lee JH Koh J Lee HK Min MY Kim  2020 Clinical efficacy and safety of injection of stromal vascular fraction derived from autologous adipose tissues in systemic sclerosis patients with hand disability: a proof-of-concept trial J Clin Med 9:3023. https:\/\/doi.org\/10.3390\/jcm9093023","journal-title":"J Clin Med"},{"issue":"8","key":"7557_CR104","doi-asserted-by":"publisher","first-page":"e0289594","DOI":"10.1371\/journal.pone.0289594","volume":"18","author":"M Iglesias","year":"2023","unstructured":"Iglesias M, Torre-Villalvazo I, Butron-Gandarillas P et al (2023) Adipose derived stromal vascular fraction and fat graft for treating the hands of patients with systemic sclerosis. A randomized clinical trial PLoS One 18(8):e0289594. https:\/\/doi.org\/10.1371\/journal.pone.0289594","journal-title":"A randomized clinical trial PLoS One"},{"issue":"8","key":"7557_CR105","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1002\/1rt.42133","volume":"74","author":"D Khanna","year":"2022","unstructured":"Khanna D, Caldron PP, Martin RW, Kafaja S, Spiera R, Shahouri S et al (2022) Adipose-derived regenerative cell transplantation for the treatment of hand dysfunction in systemic sclerosis: a randomized clinical trial. Arthritis Rheumatol 74(8):1399\u20131408. https:\/\/doi.org\/10.1002\/1rt.42133","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"7557_CR106","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1089\/wound.2012.0408","volume":"3","author":"JK Fraser","year":"2014","unstructured":"JK Fraser KC Hicok R Shanahan M Zhu S Miller DM Arm 2014 The Celution\u00ae System: automated processing of adipose-derived regenerative cells in a functionally closed system Adv Wound Care (New Rochelle) 3(1):38-45. https:\/\/doi.org\/10.1089\/wound.2012.0408","journal-title":"Adv Wound Care (New Rochelle)"},{"key":"7557_CR107","doi-asserted-by":"publisher","unstructured":"Daumas A, Magalon J, Jouve E, et al (2022) Adipose tissue-derived stromal vascular fraction for treating hands of patients with systemic sclerosis: a multicentre randomized trial autologous AD-SVF versus placebo in systemic sclerosis. Rheumatol(Oxford) 61(5):1936\u20131947. https:\/\/doi.org\/10.1093\/rheumatology\/keab584","DOI":"10.1093\/rheumatology\/keab584"},{"key":"7557_CR108","doi-asserted-by":"publisher","first-page":"650","DOI":"10.7326\/0003-4819-153-10-201011160-00007","volume":"153","author":"S Guiducci","year":"2010","unstructured":"S Guiducci F Porta R Saccardi S Guidi L Ibba-Manneschi M Manetti B Mazzanti S Pozzo Dal AF Milia S Bellando-Randone  2010 Autologous mesenchymal stem cells foster revascularization of ischemic limbs in systemic sclerosis: a case report Ann Intern Med 153:650-654. https:\/\/doi.org\/10.7326\/0003-4819-153-10-201011160-00007","journal-title":"Ann Intern Med"},{"key":"7557_CR109","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/sj.leu.2404996","volume":"22","author":"M Christopeit","year":"2008","unstructured":"M Christopeit M Schendel J F\u00f6ll LP M\u00fcller G Keysser G Behre 2008 Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L Leukemia 22:1062-1064. https:\/\/doi.org\/10.1038\/sj.leu.2404996","journal-title":"Leukemia"},{"key":"7557_CR110","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1002\/art.30431","volume":"63","author":"G Keyszer","year":"2011","unstructured":"G Keyszer M Christopeit S Fick M Schendel BM Taute G Behre LP M\u00fcller HJ Schmoll 2011 Treatment of severe progressive systemic sclerosis with transplantation of mesenchymal stromal cells from allogeneic related donors: report of five cases Arthritis Rheum 63:2540-2542. https:\/\/doi.org\/10.1002\/art.30431","journal-title":"Arthritis Rheum"},{"key":"7557_CR111","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/S2665-9913(21)00326-X","volume":"4","author":"D Farge","year":"2022","unstructured":"D Farge S Loisel M Resche-Rigon P Lansiaux I Colmegna D Langlais K Tarte 2022 Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1\/2 study Lancet Rheumatol 4:e91-e104. https:\/\/doi.org\/10.1016\/S2665-9913(21)00326-X","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"7557_CR112","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/stcltm\/szad010","volume":"12","author":"S Loisel","year":"2023","unstructured":"S Loisel P Lansiaux D Rossile  2023 Regulatory B cells contribute to the clinical response after bone marrow-derived mesenchymal stromal cell infusion in patients with systemic sclerosis Stem Cells Transl Med 12(4):194-206. https:\/\/doi.org\/10.1093\/stcltm\/szad010","journal-title":"Stem Cells Transl Med"},{"key":"7557_CR113","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13287-022-02786-3","volume":"13","author":"J Cui","year":"2022","unstructured":"J Cui L Jin M Ding J He L Yang S Cui X Wang J Ma A Liu 2022 Efficacy and safety of mesenchymal stem cells in the treatment of systemic sclerosis: a systematic review and meta-analysis Stem Cell Res Ther 13-118. https:\/\/doi.org\/10.1186\/s13287-022-02786-3","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"7557_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102831","volume":"20","author":"C-H Escobar-Soto","year":"2021","unstructured":"C-H Escobar-Soto R Mejia-Romero N Aguilera  2021 Human mesenchymal stem cells for the management of systemic sclerosis Systematic review Autoimmun Rev 20(6):102831.https:\/\/doi.org\/10.1016\/j.autrev.2021.102831","journal-title":"Systematic review Autoimmun Rev"},{"issue":"1","key":"7557_CR115","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s13287-018-1053-4","volume":"9","author":"J Liang","year":"2018","unstructured":"J Liang H Zhang W Kong  2018 Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study Stem Cells Res Ther 9(1):312. https:\/\/doi.org\/10.1186\/s13287-018-1053-4","journal-title":"Stem Cells Res Ther"},{"issue":"3","key":"7557_CR116","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1007\/s10067-024-06865-z","volume":"43","author":"M Alip","year":"2024","unstructured":"M Alip D Wang S Zhao  2024 Umbilical cord mesenchymal stem cells transplantation in patients with systemic sclerosis: a 5-year follow-up study Clin Rheumatol 43(3):1073-1082. https:\/\/doi.org\/10.1007\/s10067-024-06865-z","journal-title":"Clin Rheumatol"},{"issue":"1","key":"7557_CR117","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13287-025-04237-1","volume":"16","author":"W Yuan","year":"2025","unstructured":"Yuan W, Liu M, Yang D, Shi Y, Wang Z, Cao X et al (2025) Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study. Stem Cell Res Ther 16(1):128. https:\/\/doi.org\/10.1186\/s13287-025-04237-1","journal-title":"Stem Cell Res Ther"},{"issue":"8","key":"7557_CR118","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020479","volume":"8","author":"FCC van Rhijn-Brouwer","year":"2018","unstructured":"FCC Rhijn-Brouwer van H Gremmels JO Fledderus AH Schuurman F Bonte-Mineur MC Vonk  2018 A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS trial protocol BMJ Open 8(8):e020479.https:\/\/doi.org\/10.1136\/bmjopen-2017-020479","journal-title":"BMJ Open"},{"key":"7557_CR119","doi-asserted-by":"publisher","first-page":"48","DOI":"10.21037\/sci.2016.09.03","volume":"3","author":"T Wehbe","year":"2016","unstructured":"T Wehbe MA Saab NA Chahine T Margossian 2016 Mesenchymal stem cell therapy for refractory scleroderma: a report of 2 cases Stem Cell Investig 3:48 https:\/\/doi.org\/10.21037\/sci.2016.09.03","journal-title":"Stem Cell Investig"},{"issue":"1","key":"7557_CR120","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13075-017-1373-2","volume":"19","author":"H Zhang","year":"2017","unstructured":"H Zhang J Liang X Tang  2017 Sustained benefit from combined plasmapheresis and allogeneic mesenchymal stem cells transplantation therapy in systemic sclerosis Arthritis Res Ther 19(1)165 https:\/\/doi.org\/10.1186\/s13075-017-1373-2","journal-title":"Arthritis Res Ther"},{"key":"7557_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102476.eCollection2024","volume":"69","author":"R Greco","year":"2024","unstructured":"R Greco T Alexander N Papa Del F M\u00fcller R Saccardi F Sanchez-Guijo  2024 Innovative cellular therapies for autoimmune diseases: expert-based position statement for clinical practice recommendations from the EBMT practice harmonization and guidelines committee EClinicalMedicine 69:102476https:\/\/doi.org\/10.1016\/j.eclinm.2024.102476.eCollection2024","journal-title":"EClinicalMedicine"},{"key":"7557_CR122","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/s41409-021-01326-6","volume":"56","author":"R Greco","year":"2021","unstructured":"R Greco T Alexander J Burman N Papa Del J Vries-Bouwstra de D Farge J Henes M Kazmi K Kirgizov PA Muraro  2021 Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations Bone Marrow Transplant 56(1493):1508 https:\/\/doi.org\/10.1038\/s41409-021-01326-6","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"7557_CR123","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.3390\/ijms22073397","volume":"22","author":"Y Seo","year":"2021","unstructured":"Y Seo MJ Kang HS Kim 2021 Strategies to potentiate paracrine therapeutic efficacy of mesenchymal stem cells in inflammatory diseases Int J Mol Sci 22(7):3397 https:\/\/doi.org\/10.3390\/ijms22073397","journal-title":"Int J Mol Sci"},{"key":"7557_CR124","doi-asserted-by":"publisher","unstructured":"Ogawa Y, Morikawa S, Okano H, Mabuchi Y, Suzuki S, Yaguchi T, Sato Y, et al (2016) MHC-compatible bone marrow stromal\/stem cells trigger fibrosis by activating host T cells in a scleroderma mouse model. eLife 5:e09394. https:\/\/doi.org\/10.7554\/eLife.09394","DOI":"10.7554\/eLife.09394"},{"key":"7557_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.scr.2024.103624","volume":"82","author":"M Velier","year":"2025","unstructured":"M Velier R Appay R Arcani  2025 Generation of human induced pluripotent stem cell lines (iPSC) from adipose-derived mesenchymal stromal cells from two patients with systemic sclerosis Stem Cell Res 82:103624https:\/\/doi.org\/10.1016\/j.scr.2024.103624","journal-title":"Stem Cell Res"},{"key":"7557_CR126","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.3390\/cells10102727","volume":"10","author":"P Rozier","year":"2021","unstructured":"P Rozier M Maumus ATJ Maria K Toupet C Jorgensen P Guilpain D No\u00ebl 2021 Lung fibrosis is improved by extracellular vesicles from IFN\u03b3-primed mesenchymal stromal cells in murine systemic sclerosis Cells 10:2727 https:\/\/doi.org\/10.3390\/cells10102727","journal-title":"Cells"},{"key":"7557_CR127","doi-asserted-by":"publisher","first-page":"1492821","DOI":"10.3389\/fcell.2024.1492821","volume":"12","author":"X Wang","year":"2024","unstructured":"X Wang J Guo Q Dai 2024 Mesenchymal stem cell-derived extracellular vesicles in systemic sclerosis: role and therapeutic directions Front Cell Dev Biol 12:1492821 https:\/\/doi.org\/10.3389\/fcell.2024.1492821","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"7557_CR128","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1038\/s41598-024-72630-6","volume":"15","author":"Y Xiao","year":"2025","unstructured":"Y Xiao Q Xiang Y Wang Z Huang J Yang X Zhang  2025 Exosomes carrying adipose mesenchymal stem cells function alleviate scleroderma skin fibrosis by inhibiting the TGF-\u03b21\/Smad3 axis Sci Rep 15(1):7162 https:\/\/doi.org\/10.1038\/s41598-024-72630-6","journal-title":"Sci Rep"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07557-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07557-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07557-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:27:41Z","timestamp":1757204861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07557-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":128,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["7557"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07557-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"19 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}